Corange Ltd.
Division of Roche
Latest From Corange Ltd.
Jomed's Rising Star
Over the past three years, Jomed's sales growth has been dramatic, as the company has challenged market leaders like Guidant and AVE in the European stent marketplace. But, unlike other small cardiovascular start-ups, Jomed won't be content with a strong stent business--it is actively engaged in building a broad-based cardiovascular business that is truly global..
Prostagen Inc.
Prostagen is focusing on developing therapeutics and informatics for prostate cancer.
Following Compass' Lead
Corporate venture investment programs like Guidant's Compass walk a thin line between traditional business development and traditional venture capital investing. Compass' goal is to help Guidant find new technology early that could eventually help one of Guidant's core business groups but still earn a return on investment in the event the technology ultimately proves of no value to the corporation.
The Year in Deals: Hold That Acquisition!
After several years of intense consolidation, many medical products companies--the healthier ones, at least--seem to be taking a breather. Drug mergers are way down, while medical devices has become a buyer's market. And biotech consolidation isn't likely anytime soon. Only in slow-growing diagnostics is consolidation the rage.
Company Information
- Industry
- Pharmaceuticals
- Therapeutic Areas
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
UK
-
UK
-
Western Europe
-
Europe
- Parent & Subsidiaries
- Roche
- Senior Management
-
Dr. Erich Hunziker, CFO
Curt Engelhorn, Chmn. - Contact Info
-
Corange Ltd.
Phone: (44) 71 355 1500
36 Dover St.
London, W1XR
UK
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Corange Ltd.
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice